GSK to pay $1 billion for exclusive license to J&J's hepatitis B therapy
Reuters
Published Oct 31, 2023 07:50AM ET
Updated Nov 01, 2023 06:07AM ET
(Reuters) -GSK will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson (NYSE:JNJ)'s hepatitis B therapy, the British drugmaker said on Tuesday.
JNJ-3989 was initially developed by Arrowhead Pharmaceuticals (NASDAQ:ARWR) and licensed to Johnson & Johnson-owned Janssen in 2018.
Exclusive rights to the therapy will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, which is currently in late-stage development, the company said.
Hepatitis B, which affects an estimated 300 million people, is a life-threatening viral infection that attacks the liver and patients risk death from cirrhosis and liver cancer.
Under the terms of the deal, GSK will make upfront and potential milestone-based payments to both Janssen and Arrowhead totalling about $1 billion.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.